PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
22,802
15,622
11,698
69,429
8,676
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
8,676
Operating Expenses
Research Development
43,162
35,147
42,589
37,569
28,196
Selling General and Administrative
38,959
29,431
24,909
23,356
18,184
Total Operating Expenses
82,121
64,578
67,498
60,925
46,380
Operating Income or Loss
-59,812
-48,956
-55,800
8,504
-37,704
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-17,140
-17,421
-2,847
4,566
-1,600
Income Before Tax
-79,032
-69,289
-62,685
12,577
-39,252
Income Tax Expense
-1,536
-1,632
-11,672
1,844
-133
Income from Continuing Operations
-77,496
-67,657
-51,013
10,733
-39,119
Net Income
-77,496
-67,657
-51,013
10,806
-39,112
Net Income available to common shareholders
-77,496
-67,657
-51,013
10,806
-39,112
Reported EPS
Basic
-
-0.87
-0.73
0.15
-0.56
Diluted
-
-0.87
-0.73
0.15
-0.56
Weighted average shares outstanding
Basic
-
77,890
70,284
70,003
69,716
Diluted
-
77,890
70,284
70,155
69,716
EBITDA
-
-47,459
-54,679
10,582
-37,704